Market Place
Sourcing Support
Amgen`s marketing efforts help boost Tepezza sales
07 Aug 2024 //
FIERCE PHARMA
Amgen quarterly profit slips, obesity data on track for late 2024
06 Aug 2024 //
REUTERS
GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic
19 Jul 2024 //
FIERCE BIOTECH
Amgen 1Q Results
21 May 2024 //
CONTRACT PHARMA
Amgen CEO nabs pay raise thanks to Horizon deal
18 Apr 2024 //
FIERCE PHARMA
House committee probes FTC disclosure of info in reviewing Amgen-Horizon deal
27 Nov 2023 //
ENDPTS
Amgen plans to lay off 350 former Horizon employees after $28B buyout
25 Oct 2023 //
FIERCE PHARMA
Exclusive: Horizon CEO Tim Walbert talks M&A, FTC post-Amgen deal close
13 Oct 2023 //
ENDPTS
Amgen Completes Acquisition Of Horizon Therapeutics Plc
06 Oct 2023 //
PR NEWSWIRE
Rule 17(e) Announcement - Horizon Therapeutics plc
06 Oct 2023 //
BUSINESSWIRE
Rule 17(d) Announcement – Horizon Therapeutics plc
05 Oct 2023 //
BUSINESSWIRE
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
03 Oct 2023 //
BUSINESSWIRE
Horizon Therapeutics plc Announces New UPLIZNA Data
02 Oct 2023 //
BUSINESSWIRE
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
02 Oct 2023 //
BUSINESSWIRE
Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA
29 Sep 2023 //
BUSINESSWIRE
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
29 Sep 2023 //
BUSINESSWIRE
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
27 Sep 2023 //
BUSINESSWIRE
Horizon Named to U.S. News & World Report’s 2024 List of Best Companies
25 Sep 2023 //
PRESS RELEASE
Horizon Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
19 Sep 2023 //
BUSINESSWIRE
Q32 and Horizon Announce Dosing of First Patient in Phase 2 Trial of Bempikibart
13 Sep 2023 //
BUSINESSWIRE
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
06 Sep 2023 //
BUSINESSWIRE
Horizon Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
05 Sep 2023 //
BUSINESSWIRE
Amgen and Horizon plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
01 Sep 2023 //
BUSINESSWIRE
FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon
28 Aug 2023 //
BIOPHARMADIVE
Amgen fights FTC`s request for injunction against Horizon buyout
24 Aug 2023 //
FIERCE PHARMA
Horizon Ranks First in Overall Reputation by Rare Disease Patient Groups
23 Aug 2023 //
BUSINESSWIRE
Horizon, Roche top list for pharma reputation among rare disease patient groups
22 Aug 2023 //
ENDPTS
Amgen, Horizon urge judge to uphold constitutionality arguments against FTC
14 Aug 2023 //
ENDPTS
Horizon Therapeutics plc - Rule 2.12 Announcement
09 Aug 2023 //
BUSINESSWIRE
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
31 Jul 2023 //
BUSINESSWIRE
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
28 Jul 2023 //
BUSINESSWIRE
Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
27 Jul 2023 //
PRESS RELEASE
Amgen’s lupus bets continue to flounder, even those on the Horizon
25 Jul 2023 //
FIERCE BIOTECH
Horizon Announces PII Evaluating Daxdilimab Did Not Meet Primary Endpoint
21 Jul 2023 //
BUSINESSWIRE
Horizon adds `severe hearing impairment` warning to blockbuster`s label
20 Jul 2023 //
ENDPTS
FTC Says Settlement Talks to Resolve Blocked Amgen-Horizon Deal Have Ended
19 Jul 2023 //
BLOOMBERG
Horizon Therapeutics to Release Q2 2023 Financial Results on Aug. 8, 2023
17 Jul 2023 //
BUSINESSWIRE
Horizon`s Biologic Tepezza(teprotumumab) Receives Approval in the U.S.
17 Jul 2023 //
FDA
Viridian looks to beat Horizon`s Tepezza in thyroid eye disease
10 Jul 2023 //
FIERCE BIOTECH
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA
06 Jul 2023 //
BUSINESSWIRE
New Analysis of MRI Shows UPLIZNA Reduced Formation of Spinal Cord Lesions
30 Jun 2023 //
BUSINESSWIRE
TEPEZZA Approved in Brazil for the Treatment of Active TED
26 Jun 2023 //
PRESS RELEASE
New Data from TEPEZZA Trials Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
17 Jun 2023 //
PRESS RELEASE
Additional Data from Phase 4 TEPEZZA® Trial Presented at the Endocrine Society
17 Jun 2023 //
BUSINESSWIRE
UPLIZNA Pivotal Trial Publication Shows Accuracy of Attack Diagnoses for NMOSD
12 Jun 2023 //
BUSINESSWIRE
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
12 Jun 2023 //
BUSINESSWIRE
Horizon Therapeutics announces premium partnership with KPMG Women’s Irish Open
06 Jun 2023 //
BUSINESSWIRE
Horizon Therapeutics plc Announces Data from the TEPEZZA
05 Jun 2023 //
BUSINESSWIRE
Amgen extends retraining order in Horizon pursuit
05 Jun 2023 //
FIERCE PHARMA
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
02 Jun 2023 //
BUSINESSWIRE
Biomarker Analysis Publication Illustrates Efficacy of UPLIZNA
01 Jun 2023 //
BUSINESSWIRE
Analyses of MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented
31 May 2023 //
BUSINESSWIRE
Horizon Announces Presentation of Data on Rheumatic Diseases
23 May 2023 //
BUSINESSWIRE
US judge hearing fight over Amgen deal for Horizon eyes September trial
23 May 2023 //
REUTERS
FTC effort to stop Amgen`s Horizon takeover faces uphill fight
18 May 2023 //
REUTERS
